Pedro Valencia, VP, asset strategy, leadership, oncology, AbbVie, outlines how the company is accelerating development across ...

Pharmaceutical Executive: How is federal policy reshaping life sciences investments? John Stanford: Federal policy is ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

At the moment, FP&A in pharma is going through a complex period of change. While new technologies are making it easier to ...

Under the renewed deal, Bayer and Tsinghua University will work to enhance the drug discovery and development process across ...

Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine explains how insights from the ...

Approval was based on results from the Phase II TROPION-Lung05 trial, which showed that Datroway demonstrated a strong ...